| 1 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
The article states AI in medical imaging helps with complex analysis of images to improve clinical diagnosis. Its increasing use is due to its better technical performance and demonstrated benefits like faster and more accurate diagnoses, focusing on patient outcomes rather than just automation. |
4.1 Overview of results: “...AI usage within the healthcare imaging industry is swiftly gaining momentum as the level of technical performance becomes increasingly suitable for medical use...”
4.3 Theoretical frameworks and ad-hoc approaches used: “...AI in medical imaging contexts primarily serves a medical function and naturally has more complex considerations such as medico-legal issues and requiring regulatory approval...”
4.6 Gaps in existing research: “...Calisto et al. found that the use of an AI system with high levels of acceptability on average contributed to reducing diagnosis time by three minutes, false positives by 27%, and false negatives by 4%...” |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Acts as a second medical opinion |
|
The article highlights AI’s role in diagnostic imaging as providing support to healthcare professionals by helping in image analysis and improving diagnostic accuracy, effectively acting as a second opinion to enhance patient outcomes. |
4.1 Overview of results: “...interest in AI usage within the healthcare imaging industry is swiftly gaining momentum as the level of technical performance becomes increasingly suitable for medical use...”
4.6 Gaps in existing research: “...Calisto et al. found that the use of an AI system with high levels of acceptability on average contributed to reducing diagnosis time by three minutes, false positives by 27%, and false negatives by 4%...”
4.3 Theoretical frameworks and ad-hoc approaches used: “...AI in medical imaging contexts primarily serves a medical function...” |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
The article describes AI literacy as a general knowledge about AI, including what AI is and how it works, which is important for effective AI usage and influences healthcare professionals’ acceptability of AI. |
4.2 Commentary on studied factors underpinning AI acceptability: “AI literacy and system understanding share considerable overlap as they are concerned with what AI is and how it works. The point of difference – that AI literacy is about knowledge of AI generally while system understanding is about concrete knowledge of the specific system in the deployed context...”
4.6 Gaps in existing research: “There is some research that investigates the relationship between AI literacy and AI acceptability among healthcare professionals...” |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
The color of the AI machines |
|
The article outlines various factors influencing AI acceptability, including trust, workflow integration, system understanding, and technology receptiveness. However, it does not mention the color of AI machines as a factor. |
3.8 Factors influencing AI acceptability: “These include: user factors ... trust ...; system usage factors ... workflow integration ...; and socio-organisational-cultural factors ... system understanding ... technology receptiveness ...”
4.2 Commentary on studied factors underpinning AI acceptability:
-“The overarching categories into which these factors are organised reflect how AI acceptability is contingent upon a dynamic interplay of factors associated with the end user, the experience of interacting with an AI system, and the broader context in which AI is deployed.”
-“These should be kept in mind by medical organisations to ensure a more comprehensive, systematic approach to examining the strengths and deficiencies of their AI implementation strategy in relation to acceptability among healthcare professionals.”
The article did not mention the color of the AI machines as one of the factors that influence acceptability of AI among healthcare professionals. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Affects healthcare professionals’ decisions to use AI |
|
The article groups social influence under socio-organisational-cultural factors that impact AI acceptability, indicating it plays a role in shaping how healthcare professionals decide whether to adopt or accept AI technologies. |
4.2 Commentary on studied factors underpinning AI acceptability:
“The overarching categories into which these factors are organised reflect how AI acceptability is contingent upon a dynamic interplay of factors associated with the end user, the experience of interacting with an AI system, and the broader context in which AI is deployed.”
Social influence is explicitly mentioned as one of the “socio-organisational-cultural factors (contextual and environmental matters) encompassing social influence, organisational readiness, ethicality, and perceived threat.” |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a perceived threat regarding AI usage in healthcare settings?
|
Concerns about replacing healthcare professionals |
|
The article describes perceived threat as including fears related to the impact of AI on professional autonomy, such as concerns about the replacement or redundancy of healthcare professionals. This reflects anxiety that AI systems might reduce the role or necessity of human experts in medical practice. |
4.3 Theoretical frameworks and ad-hoc approaches used:
-“the perceived threat of AI to professional autonomy based on fears about deskilling, replacement or redundancy...”
-“issues of system transparency which can inhibit trust... and the perceived threat of AI to professional autonomy...” |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Designing human-centred AI systems |
|
The article highlights that human-centred design principles, which focus on usability and workflow integration, play an important role in increasing acceptability. For example, a study found that AI systems with high acceptability improved diagnostic speed and accuracy, showing that designing AI to fit well with users’ needs and contexts is essential. |
4.6 Gaps in existing research: “Calisto et al. was the only study to examine how system usability facilitated by human-centred design principles impacted diagnostic accuracy, productivity, and acceptability [44]. They found that the use of an AI system with high levels of acceptability on average contributed to reducing diagnosis time by three minutes, false positives by 27%, and false negatives by 4% [44].” |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
The article grouped AI acceptability factors into categories, and “system usage factors” which include practical concerns related to how healthcare professionals interact with the AI system. This specifically covers value proposition, self-efficacy, burden, and workflow integration. |
4.2. Commentary on studied factors underpinning AI acceptability:
-“The overarching categories into which these factors are organised reflect how AI acceptability is contingent upon a dynamic interplay of factors associated with the end user, the experience of interacting with an AI system, and the broader context in which AI is deployed.”
-“System usage factors (human-computer interaction and user experience concerns) entailing value proposition, self-efficacy, burden, and workflow integration...” |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
Ethicality is one of the socio-organisational-cultural factors that influence how acceptable AI is among healthcare professionals. It relates to whether the AI system aligns with professional values and ethics, which is important in shaping their trust and acceptance. |
4.2. Commentary on studied factors underpinning AI acceptability:
-“The overarching categories into which these factors are organised reflect how AI acceptability is contingent upon a dynamic interplay of factors... and the broader context in which AI is deployed.”
-“...socio-organisational-cultural factors (contextual and environmental matters) encompassing social influence, organisational readiness, ethicality, and perceived threat.” |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
The article recommends that future research should move beyond simple methods and instead deeply consider the user’s context, including how AI integrates into workflows and how professionals experience it. |
4.8 Future work and direction:
-“Where possible, researchers should endeavour to establish the user context and understand the nature of the concrete AI-assisted workflow for the participants being studied to better contextualise and inform their investigation of AI acceptability.”
-“It would be worthwhile to perform an updated review… and how methodological approaches for investigating acceptability have evolved as AI becomes increasingly integrated into medical systems.” |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
The article shows that human embryonic stem cells are used to make dopamine-producing cells that can be transplanted into the brain. These cells replace the lost dopamine neurons in Parkinson’s disease, help grow new connections, and improve movement problems in animal models. |
Introduction and Results sections: "Preclinical studies in rats have shown that transplanted hESC-derived VM progenitor cells can survive and mature into DA-producing neurons, innervate the host striatum, integrate into the host circuitry, mediate functional recovery in DA depletion models through DA secretion..."
Efficacy sections (Figure 3 and text): "STEM-PD cells survive transplantation long-term and mature into DA neurons with the capacity for long-distance fiber outgrowth and the ability to mediate full functional recovery in the DA-lesioned recipient animal."
Clinical dose calculation: "Based on previous fetal tissue transplantation trials... a minimal dose for clinical recovery was estimated as approximately 1 × 10^5 human TH+ neurons per grafted putamen..." |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Rats |
|
The article states that the STEM-PD product was tested for safety and efficacy in immunodeficient nude rats through long term transplantation studies, where they assessed survival, tumor formation, biodistribution, and functional recovery. |
Safety testing section: "A 39-week toxicity, tumorigenicity, and biodistribution study of STEM-PD batch #3 in immunodeficient athymic nude rats under full GLP conditions."
Efficacy testing section: "Efficacy, potency, and outgrowth capacity of STEM-PD batch #3 was evaluated in the unilateral 6-hydroxydopamine (6-OHDA)-lesioned model of PD with immunodeficient nude rats as recipients." |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
12 months |
|
The article describes a 39-week (approximately 9 months) GLP safety study in rats, and further mentions assessments continuing up to 12 months post-transplantation, including monitoring of cell proliferation and biodistribution. |
GLP safety testing section: "A 39-week toxicity, tumorigenicity, and biodistribution study of STEM-PD batch #3 in immunodeficient athymic nude rats."
Additional data on graft proliferation assessed at 12 months: "By 12 months, the % cycling cells and % Ki67+ cells were both <0.1%."
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I/IIa |
|
The article describes the STEM-PD clinical trial as a first-in-human study designed to assess safety, tolerability, and preliminary efficacy, which corresponds to a Phase I/IIa trial. |
Clinical trial design section: "The primary objective of the trial is to assess the safety, tolerability, and feasibility... Secondary objectives related to efficacy are assessed at 36 months."
Discussion section: "This is a first-in-human study..."
Overview of the STEM-PD trial: Figure 6 and accompanying text describe a small open-label trial with 8 patients, typical for early phase clinical trials such as Phase I/IIa. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How is the STEM-PD product manufactured?
|
Under GMP-compliant conditions |
|
The article states that the STEM-PD product is manufactured from the RC17 human embryonic stem cell line fully under Good Manufacturing Practice (GMP) conditions to ensure quality, safety, and consistency for clinical use. |
Discussion section: "When designing STEM-PD, we opted for a cryopreserved cell product from the hESC line RC17, which was derived fully under GMP conditions."
Clinical trial design section: "The STEM-PD product has been manufactured in batches large enough to allow for quality assessment and in vivo safety and efficacy, as well as use in the entire clinical trial." |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
The article states that long-term safety studies in rats showed no tumor formation or adverse effects, confirming the safety of the STEM-PD product. |
Discussion section:
-"thorough testing of the clinically administered batch for safety and efficacy in long-term animal studies gives high confidence in the functionality and safety of the exact product batch used in patients."
-"no adverse effects or tumor formation were observed in the preclinical safety study in rats."
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
Transplanted cells reversed motor deficits in rats. |
|
The article reports that in preclinical studies, transplanted STEM-PD cells survived, matured into dopamine-producing neurons, and improved motor function in rat models of Parkinson’s disease. |
Discussion section: "Preclinical studies in rats have shown that transplanted hESC-derived VM progenitor cells can survive and mature into DA-producing neurons... and mediate functional recovery in DA depletion models through DA secretion." |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
LMX1A and EN1 |
|
The article states that the purity of the STEM-PD batch was assessed by expression of key midbrain dopamine neuron markers LMX1A and EN1, which indicate correct regional identity and differentiation status. |
Methods/Results sections: "Purity of the VM progenitors was confirmed by expression of the transcription factors LMX1A and EN1..." |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They are used in cell patterning for specific neural fates. |
|
The article explains that growth factors like FGF8b and SHH are added during the manufacturing of the STEM-PD cells to guide the stem cells to become ventral midbrain neural progenitors, which are the specific cell types needed to replace dopamine neurons. |
Methods/Manufacturing section: "The protocol uses FGF8b and SHH for patterning the cells to acquire ventral midbrain identity..." |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Recovery of motor function |
|
The article describes that in the preclinical rat studies, the efficacy of the STEM-PD product was shown by the transplanted cells helping to restore normal movement, reversing motor deficits caused by dopamine loss. |
Preclinical studies section: "Transplanted hESC-derived VM progenitor cells... mediate functional recovery in DA depletion models through DA secretion..." |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|